Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
Jeffrey S. Weber(NYU Langone Health), Matteo S. Carlino(Blacktown & Mount Druitt Hospital), Adnan Khattak(Edith Cowan University), Tarek Meniawy(St John of God Subiaco Hospital), George Ansstas(Washington University in St. Louis), Matthew H. Taylor(Providence Portland Medical Center), Kevin B. Kim(California Pacific Medical Center), Meredith McKean(Sarah Cannon), Georgina V. Long(The University of Sydney), Ryan J. Sullivan(Harvard University), Mark B. Faries(Angeles Clinic and Research Institute), Thuy Tran(Yale New Haven Hospital), C. Lance Cowey(Texas Oncology), Andrew L. Pecora(Hackensack University Medical Center), Montaser Shaheen(The University of Texas at San Antonio Health Science Center), Jennifer Segar(University of Arizona), Theresa Medina(University of Colorado Cancer Center), Victoria Atkinson(Princess Alexandra Hospital), Geoffrey T. Gibney(Georgetown Lombardi Comprehensive Cancer Center), Jason J. Luke(UPMC Hillman Cancer Center), Sajeve Thomas(Orlando Health), Elizabeth I. Buchbinder(Dana-Farber Cancer Institute), Jane A Healy(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mo Huang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Manju Morrissey(Moderna Therapeutics (United States)), Igor Feldman(Moderna Therapeutics (United States)), Vasudha Sehgal(Moderna Therapeutics (United States)), Céline Robert-Tissot(Moderna Therapeutics (United States)), Peijie Hou(Moderna Therapeutics (United States)), Lili Zhu(Moderna Therapeutics (United States)), Michelle Brown(Moderna Therapeutics (United States)), Praveen Aanur(Moderna Therapeutics (United States)), Robert Meehan(Moderna Therapeutics (United States)), Tal Zaks(Moderna Therapeutics (United States))
Cited by 710
Abstract
Related Papers
No related papers found
Powered by citation graph analysis